Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,378.90up ₹20.90 (1.54%)BSE ₹1,380.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,358.00.
30 Oct: open ₹1,362.00, high ₹1,381.70, low ₹1,357.00
52-week range of traded prices to 30 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,11,397 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.45
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.15
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,36,66155.4% delivered
Cipla board and management
65 filed, newest first. Page 2 of 2.
May 2015
Sep 2014
4 Sep · Management
Mr. Pankaj Patel, Director has resigned from the directorship of the Company due to his increasing professional commitments.
Jul 2014
Mar 2014
13 Mar · Management
Feb 2014
12 Feb · Management
Board of Directors at its meeting held on February 12, 2014 have appointed Dr. Peter Mugyenyi as an Additional Director with effect from February 12, 2014 to hold office as an Independent Director of the Company.
Aug 2013
30 Aug · Management
Dr. Ranjan Pai, Director has resigned from the Directorship of the Company due to his increasing business commitments.
May 2013
Nov 2012
Nov 2011
14 Nov · Management
As under : (1) Appointment of Additional Director : The Board of Directors at its meeting held on November 14, 2011 have appointed Dr. Ranjan Pai as an Additional Director on the Board of Directors of the Company. Dr. Ranjan Pai is the Founder and Chief Executive Officer of the Manipal Education and Medical Group (MEMG), a diversified group focusing on Education, Healthcare and Research. He is a graduate of medicine from the Kasturba Medical College, Manipal after which he obtained a Fellowship in Hospital Administration in the United States. His vast experience in the area of Healthcare, Research and Education and his strong reputation and goodwill will further strengthen and broad-base the Company's Board; (2) Appointment of Chief Financial Officer : As a part of broad-basing the Company's organisational structure, Mr. V. S. Mani has been appointed as the Chief Financial Officer of the Company. Mr. V. S. Mani succeeds Mr. S. Radhakrishnan, the present Chief Financial Officer of the Company. Mr. S. Radhakrishnan, having been nominated to the Board last year, continues to be the Executive Director of the Company. Mr. V. S. Mani is a qualified Chartered Accountant and has rich experience and knowledge of pharmaceutical industry both in the domestic and international arena. He was working for Cipla until 2002 and subsequently held positions with other pharmaceutical companies such as Glenmark, Wockhardt etc. Mr. V.S. Mani's span of expertise covers the entire gamut of Finance, Information Technology, Legal and other allied areas.
Dec 2010
9 Dec · Management
Contract of Mr. Amar Lulla as Joint Managing Director of the Company will expire on December 13, 2010. Mr. Amar Lulla has informed the Company that he is not in a position to continue his services in the above capacity on expiry of his current term. In deference of his wishes, the Board has accepted his request. Consequently Mr Amar Lulla will cease to be the joint Managing Director of the Company effective from the aforesaid date. The Company would like to place on record its sincere appreciation and gratitude to Mr. Amar Lulla for his pioneering efforts during his association with the Company for over three decades. He has been one of the key persons who has played a significant role in enabling the company to attain its current position.
Nov 2010
11 Nov · Management
Board of Directors of the Company at its meeting held on November 11, 2010, have appointed Mr.S.Radhakrishnan as an Additional Director and Whole-time Director of the Company for a period of 5 years. Mr.S.Radhakrishnan is a qualified Chartered Accountant, has been with the Company for over 26 years and has rich experience in financial, commercial, legal and allied areas.11 Nov · Management
Mr. S. A. A. Pinto, Director has resigned from the Directorship of the Company due to health reasons.
Mar 2008
5 Mar · Management
Cipla Ltd. has informed the Exchange that the Board of Directors at its meeting held on March 5, 2008 appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from 5th March,2008.
Aug 2007
28 Aug · Management
Cipla Ltd. has informed the Exchange that: "Dr. M. K. Gurjar, Director has resigned from the Board of Directors due to personal reasons with effect from August 27, 2007".